Brian Hiller
Medical · Enumclaw, WANPI 1386978104
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 417 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 46 manufacturers, the largest accounting for just 21.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,479, 5.0 times the $491 reported in 2021. Among medical clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 417 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Mayne Pharma Commercial LLC$851
- Amgen$697
- Novo Nordisk$556
- AstraZeneca$330
- Lilly USA, LLC$297
- plus $3K from 40 others
What the payments were for
- Food & beverage$6,83098%
- Education$1442%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$6,974 in reported general payments places this provider in the 90th percentile of 457 medical providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 28 | $26,753 |
| JardianceEmpagliflozin | 32 | $26,314 |
| TrulicityDulaglutide | 12 | $23,784 |
| MounjaroTirzepatide | 20 | $21,799 |
| CreonLipase/Protease/Amylase | 19 | $17,117 |
| EliquisApixaban | 11 | $14,576 |
| XareltoRivaroxaban | 17 | $12,969 |
| Repatha SureclickEvolocumab | 17 | $9,544 |
| XiidraLifitegrast | 12 | $8,448 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $7,283 |
| Spiriva HandihalerTiotropium Bromide | 12 | $6,184 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $2,834 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 115 | $1,524 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 51 | $1,447 |
| Omeprazole | 45 | $1,091 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $297 | $45,58432 claims |
| Novo NordiskOzempic | $556 | $26,75328 claims |
| Boehringer IngelheimJardiance | $172 | $26,31432 claims |
| AbbVieCreon | $1,464 | $17,11719 claims |
| PfizerEliquis | $239 | $14,57611 claims |
| Johnson & JohnsonXarelto | $92 | $12,96917 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $330 | $10,11723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 457 medical providers in Washington.
Other medical in Enumclaw
- Merlie SedanEnumclaw$3K
- Diana McFarlaneSeattle$95K
- Karissa SecoraTacoma$53K
- Tori FranklinLakewood$23K
- Salvador LopezYakima$17K
- Amy NelsonSeattle$15K
- Rebecca JohnsonSpokane$14K
- Jonathan CyphersBurien$13K
- Jonathan WhiteSeattle$13K
- Julia TaylorSpokane$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.